导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.19% | 1877/4773 |
| 近一周 | 0.85% | 163/5458 |
| 近一月 | 2.30% | 370/5421 |
| 近一季 | 0.21% | 1018/5205 |
| 近半年 | -1.60% | 1864/4920 |
| 近一年 | 3.04% | 2170/4361 |
| 近两年 | 25.89% | 2500/2954 |
| 近三年 | 26.49% | 1223/2253 |
| 成立以来 | 89.05% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.24% 997/4961 |
-8.35% 3877/5312 |
- - |
- - |
| 2025 | 1.93% 3208/4813 |
-1.77% 2776/3635 |
3.01% 1203/4076 |
-2.02% 3976/4524 |
2.81% 843/4813 |
| 2024 | 28.93% 141/3463 |
10.39% 64/2808 |
3.48% 268/3014 |
10.83% 2587/3129 |
1.85% 1016/3463 |
| 2023 | 14.25% 46/2656 |
10.95% 357/2280 |
5.89% 56/2385 |
2.44% 234/2515 |
-5.07% 1248/2655 |
| 2022 | -4.20% 83/2207 |
-1.42% 146/1919 |
-1.43% 1721/2016 |
-4.76% 61/2113 |
3.53% 677/2208 |
| 2021 | 16.90% 255/1822 |
10.37% 40/1255 |
-0.70% 1147/1330 |
7.44% 188/1466 |
-0.72% 1270/1822 |
| 2020 | - - |
- - |
-0.74% 1024/1067 |
9.64% 636/1164 |
5.15% 803/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 南方红利低波50ETF联接C VS. 长安沪深300非周期A(740101) |